Monoclonal antibody therapy of cancer Book Section


Authors: Jurcic, J. G.; Mulford, D. A.; Scheinberg, D. A.
Editors: Kaufman, H. L.; Wolchok, J. D.
Article/Chapter Title: Monoclonal antibody therapy of cancer
Abstract: After two decades of preclinical and clinical trials, monoclonal antibodies (mAbs) are now used routinely in the treatment of cancer. The development of hybridoma technology, first described by Köhler and Milstein in 1975, allowed the therapeutic potential of mAbs to be explored [1]. With the promise to target and destroy malignant cells selectively, mAbs were initially seen as "magic bullets." Early studies, however, revealed various physical, biological, and immunological limitations to their clinical use. Advances in immunology and molecular biology allowed many obstacles to the effective use of mAbs to be surmounted. Genetically engineered chimeric, humanized, and fully human antibodies have been developed to overcome the lack of intrinsic antitumor activity of many murine mAbs. Because host effector mechanisms are not required for tumor killing, radioimmunotherapy and antibody-drug conjugates have also become promising approaches.
Book Title: General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology
ISBN: 978-1-4020-6086-1
Publisher: Springer Netherlands  
Publication Place: Dordrecht, Netherlands
Date Published: 2007-01-01
Start Page: 321
End Page: 342
Language: English
DOI: 10.1007/978-1-4020-6087-8_14
PROVIDER: scopus
DOI/URL:
Notes: Book chapter 14 -- Gen. Principles of Tum. Immunotherapy: Basic and Clin. Applic. of Tum. Immunol. -- 9781402060878 (ISBN); 9781402060861 (ISBN) -- Export Date: 2 January 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph G Jurcic
    134 Jurcic